BR112015023806A2 - Novos regimes de dosagem de celgosivir para o tratamento de dengue - Google Patents

Novos regimes de dosagem de celgosivir para o tratamento de dengue

Info

Publication number
BR112015023806A2
BR112015023806A2 BR112015023806A BR112015023806A BR112015023806A2 BR 112015023806 A2 BR112015023806 A2 BR 112015023806A2 BR 112015023806 A BR112015023806 A BR 112015023806A BR 112015023806 A BR112015023806 A BR 112015023806A BR 112015023806 A2 BR112015023806 A2 BR 112015023806A2
Authority
BR
Brazil
Prior art keywords
dengue
celgosivir
treatment
new
formula
Prior art date
Application number
BR112015023806A
Other languages
English (en)
Inventor
Vasudevan Subhash
Sung Cynthia
Rathore Abhay
Watanabe Satoru
Low Jenny
Eong Ooi Eng
S Dow Geoffrey
Morish Glynn
Reid Mark
Original Assignee
Watanabe Satoru
Vasudevan Subhash
Sung Cynthia
Rathore Abhay
Low Jenny
Eong Ooi Eng
Nat Univ Singapore
60º PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watanabe Satoru, Vasudevan Subhash, Sung Cynthia, Rathore Abhay, Low Jenny, Eong Ooi Eng, Nat Univ Singapore, 60º PHARMACEUTICALS LLC filed Critical Watanabe Satoru
Publication of BR112015023806A2 publication Critical patent/BR112015023806A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

NOVOS REGIMES DE DOSAGEM DE CELGOSIVIR PARA O TRATAMENTO DE DENGUE. Métodos de tratamento de infecção pelo vírus da dengue (DENV) em um indivíduo humanos, compreendendo administração ao indivíduo humano um composto de fórmula (I), ou composição farmacêutica compreendendo uma fórmula (I): Um composto de fórmula (I) pode ser administrado dentro do início da febre a 72 horas do início da febre devido a infecção de dengue e então a cada 6 a 12 horas até que haja uma melhora na infecção ou entre cerca de 1 dia a cerca de 10 dias. Os métodos da invenção podem ser usados para tratar infecções virais DENV1-4 primária ou secundária.
BR112015023806A 2013-03-15 2014-03-14 Novos regimes de dosagem de celgosivir para o tratamento de dengue BR112015023806A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798100P 2013-03-15 2013-03-15
US201361911795P 2013-12-04 2013-12-04
PCT/US2014/028076 WO2014143907A1 (en) 2013-03-15 2014-03-14 Novel dosing regimens of celgosivir for the treatment of dengue

Publications (1)

Publication Number Publication Date
BR112015023806A2 true BR112015023806A2 (pt) 2017-08-22

Family

ID=51537558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023806A BR112015023806A2 (pt) 2013-03-15 2014-03-14 Novos regimes de dosagem de celgosivir para o tratamento de dengue

Country Status (8)

Country Link
US (3) US9763921B2 (pt)
AU (1) AU2014228035B2 (pt)
BR (1) BR112015023806A2 (pt)
MX (1) MX2015013115A (pt)
MY (1) MY170991A (pt)
PH (1) PH12015502128A1 (pt)
SG (2) SG10201908089VA (pt)
WO (1) WO2014143907A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908089VA (en) * 2013-03-15 2019-10-30 60 Pharmaceuticals Llc Novel dosing regimens of celgosivir for the treatment of dengue
US11000516B2 (en) * 2015-12-11 2021-05-11 60 Degrees Pharmaceuticals, LLC Dosing regimens of celgosivir for the prevention of dengue
WO2018017426A1 (en) 2016-07-16 2018-01-25 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
US10555942B2 (en) 2017-10-10 2020-02-11 Florida State University Research Foundation, Inc. Emetine compounds for treatment and prevention of flavivirus infection
US11369592B2 (en) 2020-02-21 2022-06-28 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234596A1 (en) 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
GB0401238D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Immunomodulatory alkaloids
SG10201908089VA (en) * 2013-03-15 2019-10-30 60 Pharmaceuticals Llc Novel dosing regimens of celgosivir for the treatment of dengue

Also Published As

Publication number Publication date
US20160030403A1 (en) 2016-02-04
AU2014228035A1 (en) 2015-09-24
US11219616B2 (en) 2022-01-11
US20180064693A1 (en) 2018-03-08
WO2014143907A1 (en) 2014-09-18
SG11201507254VA (en) 2015-10-29
US10517854B2 (en) 2019-12-31
MX2015013115A (es) 2016-06-21
PH12015502128A1 (en) 2016-01-25
SG10201908089VA (en) 2019-10-30
US9763921B2 (en) 2017-09-19
MY170991A (en) 2019-09-23
US20200338050A1 (en) 2020-10-29
AU2014228035B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112017016006A2 (pt) composto, composição farmacêutica, método de tratamento de doenças e condições, uso de um composto e de uma combinação, e, combinação.
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
NZ607580A (en) N-heteroaryl compounds
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112019005995A2 (pt) cristal não solvatado, método de preparação e aplicação do mesmo
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112015009504A2 (pt) inibidores de rock

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]